Profile data is unavailable for this security.
About the company
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2022
- Employees3.00
- LocationCadrenal Therapeutics Inc822 A1a North, Suite 300PONTE VEDRA 32082United StatesUSA
- Phone+1 (904) 300-0701
- Fax+1 (302) 655-5049
- Websitehttps://www.cadrenal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 6.23m | 389.00 | 0.0011 | 0.0001 | 0.6752 | 0.1094 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 6.35m | 208.00 | -- | 0.9165 | 15.88 | 0.1808 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| Enveric Biosciences Inc | 0.00 | -15.11m | 6.36m | 7.00 | -- | 0.9226 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 6.57m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Ainos Inc | 93.68k | -14.56m | 6.66m | 46.00 | -- | 0.2872 | -- | 71.11 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 6.68m | 8.00 | -- | 0.3358 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| TFF Pharmaceuticals Inc | 885.71k | -19.93m | 6.85m | 19.00 | -- | 1.05 | -- | 7.73 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.87m | 5.00 | -- | 0.553 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 6.88m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 6.90m | 22.00 | -- | 0.3626 | -- | 0.5903 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.01m | 6.92m | -- | -- | 3.24 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | -- | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Scorpius Holdings Inc | 2.23m | -46.05m | 6.93m | 77.00 | -- | 0.0756 | -- | 3.11 | -1.78 | -2.00 | 0.0859 | 1.39 | 0.0234 | -- | 0.6762 | 28,918.57 | -50.05 | -38.42 | -61.25 | -42.06 | 29.10 | -- | -2,136.28 | -703.02 | -- | -- | 0.2305 | -- | 202.12 | 33.24 | -23.85 | -- | 218.50 | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 6.97m | 8.00 | -- | 1.64 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| Longeveron Inc | 978.00k | -21.62m | 6.98m | 23.00 | -- | 0.9109 | -- | 7.14 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
Data as of May 24 2024. Currency figures normalised to Cadrenal Therapeutics Inc's reporting currency: US Dollar USD
10.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 1.35m | 8.43% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 148.14k | 0.93% |
| Citadel Securities LLCas of 31 Mar 2024 | 55.85k | 0.35% |
| Geode Capital Management LLCas of 31 Mar 2024 | 42.87k | 0.27% |
| Virtu Americas LLCas of 31 Mar 2024 | 32.38k | 0.20% |
| Avantax Planning Partners, Inc.as of 31 Mar 2024 | 28.31k | 0.18% |
| XTX Markets LLCas of 31 Mar 2024 | 19.74k | 0.12% |
| Biltmore Family Office LLCas of 31 Mar 2024 | 11.00k | 0.07% |
| Tower Research Capital LLCas of 31 Mar 2024 | 9.52k | 0.06% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 54.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
